This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
by Zacks Equity Research
PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.
RHHBYNegative Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change
biotechs
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Rigel Pharmaceuticals climbs 59% in a year as Tavalisse anchors growth, oncology gains traction and 2026 guidance points to sustained momentum.
SNYNegative Net Change LLYPositive Net Change RIGLPositive Net Change
biotechs medical pharmaceuticals
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.
ALKSNegative Net Change VRTXPositive Net Change CRSPPositive Net Change CSTLPositive Net Change
biotechs earnings
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates
by Zacks Equity Research
MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and reaffirming 2026 outlook.
MRKPositive Net Change VRTXPositive Net Change MRNAPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
AGIO beats fourth-quarter estimates for both the top and bottom lines as Pyrukynd sales jump 49% year over year.
ALKSNegative Net Change EXELPositive Net Change AGIONegative Net Change CSTLPositive Net Change
biotechs
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
by Zacks Equity Research
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
NVSPositive Net Change ALKSNegative Net Change BAYRYPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.
REGNPositive Net Change ALKSNegative Net Change RARENegative Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
by Zacks Equity Research
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
ALNYPositive Net Change NVSPositive Net Change RHHBYNegative Net Change ALKSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.
ALKSNegative Net Change VRTXPositive Net Change CRSPPositive Net Change CSTLPositive Net Change
biotechs cell-therapy crispr gene-editing gene-therapy medical
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
by Ekta Bagri
Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals